an important risk indicator. [2] [3] [4] [5] [6] [7] [8] [9] [10] None of these studies has examined the rates of eGFR decline by class of antihypertensive medication, nor the relative effect of these medications on specific cardiovascular end points.
In the present study, we conducted a secondary analysis of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to determine the effects of eGFR change during the first 2 years of the trial on CHD, stroke, heart failure (HF), end-stage renal disease (ESRD), and all-cause mortality outcomes. We adjusted these analyses for baseline eGFR so as to study the effect of the eGFR change. We further examined the interaction of eGFR changes on outcomes by the primary antihypertensive medication used in the trial to ascertain for differences in outcomes.
METHODS
ALLHAT was a randomized double-blind active-controlled antihypertensive treatment trial that compared firststep treatment with the diuretic chlorthalidone (n = 15,255) to first-step treatment with the calcium channel blocker amlodipine (n = 9,048), the alpha-receptor blocker doxazosin (n = 9,061), or the angiotensin-converting enzyme inhibitor lisinopril (n = 9,054). 11 The doxazosin arm was stopped early due to a higher risk of cardiovascular disease (CVD), especially HF, compared to chlorthalidone and is not considered here. 12 All participants gave written informed consent, and all centers obtained institutional review board (IRB) approval for the trial. The IRB of The University of Texas Health Science Center at Houston approved the post-trial follow-up study. The study adhered to the Declaration of Helsinki.
Eligible participants were men and women, ≥55 years, who had a systolic blood pressure (SBP) 140-180 mm Hg, and/or a diastolic BP (DBP) 90-110 mm Hg, and/or took medication for HTN (<3 drugs), and had at least one additional risk factor for CHD, including pre-existing CVD. 11 Exclusion criteria included myocardial infarction, stroke, angina pectoris within 6 months of study entry; symptomatic HF or ejection fraction <35%; creatinine level ≥2 mg/dl; and SBP >180 mm Hg or DBP >110 mm Hg on 2 separate readings during screening. 11
Medications
The step 1 study medications were formulated to look alike so that the identity of each agent was double-masked. The dose of each step 1 blinded medication was titrated to achieve a BP of <140/90 mm Hg. If the goal BP was not achieved using a full dose of the assigned step 1 medication, an open-label step 2 antihypertensive medication (reserpine, clonidine, or atenolol) and if needed a step 3 medication (hydralazine) could be added.
Recruitment and follow-up
Recruitment was conducted from February 1994 to January 1998. Trial follow-up ended in March 2002. Follow-up visits were conducted following 1, 3, 6, 9, and 12 months of treatment, and every 4 months thereafter. The range of possible trial follow-up was 3 years and 8 months to 8 years and 1 month. Extended post-trial passive surveillance for mortality was conducted for 5 additional years, through the end of 2006, using national databases. 13 
Laboratory
Baseline laboratory test results for glucose, lipids, creatinine, and potassium levels were obtained after an overnight fast. A central laboratory performed the analyses. Serum creatinine levels were measured at 1 month and at years 1, 2, 4, and 6 and eGFR was calculated using the CKD-Epi formula. 14 
CVD endpoints
Morbidity data were available for the in-trial period. Events were ascertained by the investigator and confirmed by the coordinating center endpoints department based on discharge summaries. In-trial nonfatal events were also ascertained using Centers for Medicare and Medicaid Services in-patient claim data public access reports. Outcomes included: CHD (hospitalized nonfatal and fatal myocardial infarction); stroke; hospitalized and fatal HF; and ESRD.
Mortality endpoints
Mortality data were available for the entire cohort during both the in-trial and post-trial periods, except for the Canadian participants (n = 553) for whom post-trial data were not available. During the trial, most causes of death were determined by clinical center investigators. Additional in-trial and all post-trial all-cause and cause-specific mortality were ascertained from the National Death Index using social security number, name, sex, and date of birth as matching criteria (see the study of Cushman et al. 13 for full details of data capture). Total mortality was assessed.
Analysis
Two-year change in eGFR was measured as the change above (i.e., less eGFR decline) or below the median (i.e., greater eGFR decline) of the cohort, and as a continuous variable (per 5 ml/min/1.73 m 2 /year decline in eGFR). Endpoints by change in eGFR were evaluated using hazard ratios (HRs) from unadjusted and adjusted Cox regressions. The latter analyses were adjusted for age at baseline, treatment group, Black race, male sex, history of atherosclerotic CVD, diabetes, current smoking at baseline, and baseline eGFR, SBP, DBP, and total cholesterol. The 5 th decile of eGFR change in the total cohort was used as a reference value to determine whether eGFR change was above (less eGFR change) or below the median (more eGFR change). Interaction terms evaluated possible differential effects of change in eGFR with treatment group. We further examined whether results were the same or differed by baseline eGFR equal to or above 60 ml/min/1.73 m 2 or below it.
RESULTS
The number of participants from ALLHAT with eGFR measurements at baseline and year 2, categorized by the primary randomized antihypertensive medication, is shown in Supplementary Figure 1 . Of the 33,357 participants at baseline, 20,207 (60.6%) had baseline and 2-year eGFR values. Excluded participants were more likely to be Black and to have diabetes, and were less likely to be male (Supplementary  Table 1 ). Otherwise, only small differences existed between those included and excluded from analyses; on account of large numbers, most differences attained statistical significance.
Baseline characteristics of the cohort, categorized by the primary antihypertensive medication and eGFR change, are shown in Supplementary Table 2 . Participants with an eGFR slope change below the median (i.e., greater eGFR decline) were younger, more likely to be male, African American, have diabetes, and to smoke, but less likely to have a history of atherosclerotic CVD than participants with an eGFR change above the median. In all 3 medication groups, participants with slope of eGFR change below the median had a slightly higher baseline SBP and DBP compared to those whose eGFR change was above the median. During followup, both participants with eGFR slope above or below the median had declines in SBP and DBP. Those with eGFR change slope below the median had 2-3 and 1-2 mm Hg greater declines in SBP and DBP. Baseline eGFR values were higher and 2 year eGFR levels were lower in participants whose slope of eGFR change was below the median compared to those above the median.
The mean eGFR level at baseline was 74.7 ml/min/1.73 m 2 . The mean eGFR change during the first 2 years of the trial was −3.6 ml/min/1.73 m 2 (a slope of −1.8 ml/min/1.73 m 2 / year). The median eGFR change was −1.28 ml/min/1.73 m 2 . eGFR change in the chlorthalidone, amlodipine, and lisinopril treatment groups at 1, 2, 4, and 6 years of in-trial follow up are shown in Supplementary Table 3 . Participants assigned to chlorthalidone had significantly higher rates of eGFR decline compared to the other 2 groups, especially compared to participants on amlodipine. At 2 years, the median eGFR decline was −1.41, −1.08, and −1.32 ml/min/1.73 m 2 , respectively. Based on 2-year eGFR changes, 54.1%, 41.0%, and 51.9% of participants randomized to chlorthalidone, amlodipine, and lisinopril, respectively, had an eGFR change below the cohort median (i.e., greater eGFR decline). In all years, eGFR change in those treated with amlodipine was greater than in those treated with chlorthalidone, and in all years (but one) for those treated with lisinopril.
Risk of CVD and ESRD outcomes by eGFR change during the in-trial period Figure 1 displays unadjusted and adjusted HRs (95% confidence interval) for CHD. All 3 treatment groups had significantly higher risk for CHD per 5 ml/min/1.73 m 2 /year decrease in eGFR (HR: 1.13 to 1.17), though results were less consistent when examined by eGFR change above or below the median decline. There were no significant interaction terms between chlorthalidone and the other 2 medications.
Stroke and hospitalized and fatal HF outcomes are shown in Supplementary Figures 2 and 3 . There was no effect of the rate of eGFR change on stroke outcome by either method of eGFR decline in the 3 medication classes other than a 5-unit decline in eGFR in participants treated with amlodipine. Interaction terms were not significant. For HF, change in eGFR, either above or below the cohort median or as a continuous variable, was associated with increased risk in all 3 medication classes. The highest risks were for people treated with amlodipine; however, interaction terms were not significant. When the above analyses (CHD, stroke, HF) were categorized by eGFR equal to or above 60 ml/min/1.73 m 2 vs. below that level at baseline, there were no significant differences in outcomes between them (data not shown).
In-trial ESRD analysis is shown in Figure 2 . Either definition of eGFR decline was associated with a risk for ESRD in all 3 medication classes. eGFR decline of 5 ml/min/1.73 m 2 /year was associated with a higher risk for ESRD in participants treated with amlodipine than participants treated with chlorthalidone (P interaction = 0.005). When the association of in-trial ESRD risk with a 5 ml/min/1.73 m 2 /year decline was examined by baseline eGFR above or equal to or below 60 ml/min/1.73 m 2 , participants with lower eGFR had a significantly higher risk of ESRD (2. Raw data for the above outcomes are shown in Supplementary Table 4 .
Risk of in-trial and in-trial and post-trial total mortality by rate of eGFR decline
Supplementary Figure 4 displays unadjusted and adjusted HRs (95% confidence interval) for total mortality in the 3 treatment groups during the in-trial period. In all 3 treatment groups there were similar HRs by either measure of eGFR change and there were no significant interaction terms between treatments. Figure 3 shows HRs (95% confidence interval) for total mortality in the 3 treatment groups during the in-trial and post-trial periods combined. Participants treated with amlodipine had higher HR than the other 2 treatment groups by either measure of eGFR change but the interaction terms were not significant.
When the above 2 outcomes were categorized by eGFR equal to or above 60 ml/min/1.73 m 2 vs. below that level at baseline, there was no significant difference for a 5 ml/min/1.73 m 2 /year decline for in-trial mortality. There was a trend for a difference between them during combined in-trial and post-trial follow up (1.23 [1.17, 1.29] vs. 1.10 [1.07, 1.13]; P = 0.06) (data not shown).
Raw data for these outcomes are shown in Supplementary  Table 4 .
DISCUSSION
There are 2 main findings from this study of adults with HTN, at high risk for CVD, which assessed the effect of 2 measures of renal function decline with CVD, ESRD, and all-cause mortality outcomes.
First, a rapid change in eGFR was a strong risk factor for follow up HF and for ESRD. It was a weaker, but statistically significant, risk factor for CHD. It was not a risk factor for stroke. These findings were adjusted for baseline eGFR, suggesting that the change in eGFR added to the risk of outcomes beyond the effects of the baseline eGFR (multiplicative effect). Aside from ESRD, these findings were the same whether the baseline eGFR was equal to or above 60 ml/ min/1.73 m 2 vs. below it. Our findings are consistent with other reports of the effects of rapid rates of eGFR change on ESRD, 7,9,10 HF, 3,15 CHD, 2,3,15 and stroke. 3, 15 Why change in eGFR does not impact stroke risk cannot be determined here. Regarding mortality our estimates are similar to those from the ARIC study, 2 but lower than those from other studies which report HR of ~1.5-1.8 for rapid eGFR decline. [4] [5] [6] Differences in population characteristics and definitions of rapid eGFR decline may account for this discrepancy. Our Figure 2 . In-trial end-stage renal disease, unadjusted (left) and adjusted (right) by treatment group. Abbreviation: eGFR, estimated glomerular filtration rate.
finding that total mortality does not differ significantly for a 5 ml/min/1.73 m 2 /year decline between participants with baseline eGFR ≥60 ml/min/1.73 m 2 vs. below that level is consistent with the meta-analysis by Coresh et al. 7 ( Table e16) .
The second, and novel, finding of this study was that there was no difference in the CVD and mortality outcomes by the primary medications used to treat the underlying HTN even though eGFR decline was highest with chlorthalidone use. In prior ALLHAT reports, chlorthalidone was more protective against HF than lisinopril or amlodipine during the intrial period, 16 but such an effect was not present here. This suggests that the effect of rapid eGFR decline on HF outweighs the benefits of chlorthalidone on HF. Only in the case of ESRD was there a difference between treatment groups: participants treated with chlorthalidone had significantly "lower" risk than participants treated with amlodipine. This latter finding can be understood in 2 ways. On the one hand, many analyses were performed here, so this outcome may have occurred by chance. Alternatively, eGFR decline while on amlodipine therapy may be especially inimical for the development of ESRD. In a prior ALLHAT report, 17 we demonstrated that at 4 years of in-trial follow-up, eGFR was 3 to 6 ml/min/1.73 m 2 higher on average in patients assigned to amlodipine compared with chlorthalidone. Rapid decline in eGFR on amlodipine may therefore be associated with a higher burden of factors leading to renal decline.
Two other points should be mentioned. The HR for combined in-trial and post-trial mortality was higher than that for in-trial CHD, stroke, and mortality. An explanation for this could be that with longer follow-up and the accrual of a larger number of outcomes that the effect of eGFR change becomes more evident. Alternatively, the factors that lead to eGFR decline are more strongly associated with mortality than with CVD. Rapid decline in eGFR may impact conditions associated with worsening renal function such as frailty, 18 falls and fractures, 19 and cognitive impairment. 20 Second, participants with higher eGFR at baseline had steeper declines of eGFR over 2-years than those with lower baseline eGFR. This observation may reflect regression to the mean.
The cohort for this study was well-characterized. It was homogenous-all participants were treated for HTN and were at high risk for CVD. This is not found in population-based studies which are heterogeneous. Creatinine levels were measured in a central lab and were therefore standardized. We examined the effects of individual antihypertensive medications on outcomes, which previous studies have not done. Multiple outcomes were examined simultaneously based on granular data, unavailable in population studies. The mean eGFR change through year 2 was −3.6 ml/min/1.73 m 2 (−1.8 ml/min/1.73 m 2 /year). This outcome is approximately 40% higher than the eGFR decline in healthy adults, ages 30-59 years, based on the Baltimore Longitudinal Aging Study using inulin clearance. 21 Given the older age and heavy burden of chronic disease in our cohort, our calculation appears to be reasonable. Limitations of this study include the exclusion of people with creatinine levels ≥2 mg/dl, so our findings are not applicable to more advanced kidney disease. ALLHAT did not collect urine samples for albuminuria, an important determinant of cardiovascular and mortality outcomes. There was also some cross-over in medication use during the in-trial period. 16 Such cross-over weakens the estimates reported here for the primary study medications, so our estimates are conservative. In conclusion, decline in eGFR over a 2-year period of time was strongly associated with increased risks of ESRD and HF, and with mildly increased risks of CHD and mortality in the short run. There was no association with stroke risk. In the long run, decline in eGFR over 2-years was associated with mildly increased risk of total mortality. These results were over and above the impact of baseline eGFR levels. These findings were generally the same regardless of the primary medication used to treat the underlying HTN.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of Hypertension online.
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